Novel nucleic acid and amino acid sequences
OwnerKinneret Savitzky, Liat Mintz +2inventors
InventorsKinneret Savitzky, Liat Mintz, Anat David, Idit Azar
Life of this patent
Estimating the term…
Abstract
The invention concerns novel nucleic acid sequences, amino acid sequences coded thereby and method of detection using the above. The novel nucleic acid sequences are naturally occurring splice variants of a prostate specific antigen sequence (PSA) or of the KLK-2 gene.
Claims61
An isolated nucleic acid sequence selected from:
- (i) the nucleic acid sequence set forth in any one of SEQ ID NO:
- 1 to SEQ ID NO:
- 6;
- (ii) nucleic acid sequence having at least 90% identity with the entire length of the sequence of (a) and
- (iii) fragments of (a) or (b) of at least 20 consecutive nucleotides provided that the fragment contains a sequence which is not present in the original sequence of PSA from which the sequences of (a) have been varied by alternative splicing.
An isolated nucleic acid sequence coding for an isolated amino acid sequence of SEQ ID NO:
- 7 to SEQ ID NO:
- 12.
A method for identifying a candidate compound capable of binding to a PSA variant product and modulating its activity, the method comprising:
- (i) providing a polypeptide comprising an amino acid sequence as set forth in any one of SEQ ID NOS:
- 7 to 12, or a fragment of such a sequence, having at least 10 consecutive amino acids;
- (ii) contacting a candidate compound with the amino acid sequence;
- and
- (iii) determining the effect of the candidate compound on the biological activity of the polypeptide and selecting those candidate compounds that show a significant effect on the biological activity.
A method of eliciting an immune response in a mammal, the method comprising administering to the mammal an amount of a PSA variant product effective to generate antibodies or cause proliferation of PSA variant product-specific immune cells within the mammal.
A method of targeting a compound to tumor cells expressing a PSA variant product in an individual, the method comprising:
- (i) conjugating the compound to an antibody that binds specifically to a PSA variant product to form a conjugate;
- (ii) administering to the individual an amount of the conjugate effective to deliver the compound to the tumor cells, thereby targeting the compound to the tumor cells expressing the PSA variant product.
A method of expressing PSA variant polypeptides in vivo in an individual, the method comprising introducing into cells of the individual a PSA variant sequence that encodes a PSA product, thereby expressing a PSA variant polypeptide in vivo.
Dependencies are inferred from the claim text.